Literature DB >> 11683911

Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release.

M Marti1, F Paganini, S Stocchi, C Bianchi, L Beani, M Morari.   

Abstract

The effect of metabotropic glutamate receptor agonists and antagonists on KCl (20 mm)-induced endogenous acetylcholine release from rat striatal synaptosomes was investigated. The group I agonist (S)-3,5-dihydroxyphenylglycine (DHPG), 1-1000 nm, potentiated in a concentration-dependent way the KCl-induced acetylcholine release, reaching maximal efficacy at 100 nm (+93 +/- 14%). The effect of DHPG (10 nm) was counteracted by coapplication of (7-hydroximino)cyclopropan-b-chromen-1a-carboxylate (CPCCOEt), 10 microm, a metabotropic glutamate receptor type one selective antagonist, and 2-methyl-6-(phenylethynyl)pyridine (MPEP), 10 microm, a metabotropic glutamate receptor type five selective antagonist, but not by application of either antagonist alone. The group II agonist (2S, 1'R, 2'R, 3'R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV), 1-1000 nm, inhibited in a concentration-dependent way the KCl-induced acetylcholine release displaying maximal efficacy at 300 nm (-32 +/- 2%). The effect of DCG-IV 300 nm was counteracted by the group II selective antagonist (2S)-alpha-ethylglutamic acid (EGLU), 300 microm. The group III agonist L-amino-4-phosphonobutyric acid (L-AP4) failed to alter the KCl-induced acetycholine release up to 300 microm. We conclude that metabotropic glutamate receptors belonging to group I and II are located on the axon terminals of striatal cholinergic interneurons, their activation resulting in facilitation and inhibition, respectively, of acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683911     DOI: 10.1046/j.0953-816x.2001.01750.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  9 in total

1.  Activation of group I metabotropic glutamate receptors depresses recurrent inhibition of motoneurons in the neonatal rat spinal cord in vitro.

Authors:  Cristina Marchetti; Giuliano Taccola; Andrea Nistri
Journal:  Exp Brain Res       Date:  2005-07-01       Impact factor: 1.972

Review 2.  Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module.

Authors:  Sergi Ferré; Luigi F Agnati; Francisco Ciruela; Carme Lluis; Amina S Woods; Kjell Fuxe; Rafael Franco
Journal:  Brain Res Rev       Date:  2007-01-27

3.  Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum.

Authors:  Kari A Johnson; Yolanda Mateo; David M Lovinger
Journal:  Neuropharmacology       Date:  2017-01-31       Impact factor: 5.250

Review 4.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

5.  Group II metabotropic glutamate receptors in the striatum of non-human primates: dysregulation following chronic cocaine self-administration.

Authors:  T J R Beveridge; H R Smith; M A Nader; L J Porrino
Journal:  Neurosci Lett       Date:  2011-03-31       Impact factor: 3.046

6.  Glutamate regulates the frequency of spontaneous synchronized Ca2+ spikes through group II metabotropic glutamate receptor in cultured mouse cortical networks.

Authors:  Fumie Yasumoto; Takayuki Negishi; Yoshiyuki Ishii; Shigeru Kyuwa; Yoichiro Kuroda; Yasuhiro Yoshikawa
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

7.  Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.

Authors:  E Luccini; V Musante; E Neri; M Brambilla Bas; P Severi; M Raiteri; A Pittaluga
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 8.  Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.

Authors:  Srijan Acharya; Kyeong-Man Kim
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

9.  Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.

Authors:  Daniela Mercatelli; Paolo Bolognesi; Martina Frassineti; Clarissa A Pisanò; Francesco Longo; Derya R Shimshek; Michele Morari
Journal:  Pharmacol Res Perspect       Date:  2019-05-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.